Stock Events

Stock Events

IMV 

¥2,070
24
-¥13-0.62% 06:30 Today

Statistics

Day High
2,200
Day Low
2,029
52W High
4,255
52W Low
1,736
Volume
96,200
Avg. Volume
118,306
Mkt Cap
17.27B
P/E Ratio
8.64
Dividend Yield
1.45%
Dividend
30

Upcoming

Dividends

1.45%Dividend Yield
Sep 26
¥30
Dec 25
¥30
Dec 24
¥20
Dec 23
¥12
Dec 22
¥10
10Y Growth
16.53%
5Y Growth
28.69%
3Y Growth
44.22%
1Y Growth
50%

Earnings

6NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
5.01
22.73
40.45
58.17
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-5.05BNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap58.11B
Moderna, Inc. is a competitor because it also focuses on mRNA technology for developing vaccines and therapeutics, similar to IMV's delivery platform for immunotherapies.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech SE operates in the same space as IMV, developing and commercializing immunotherapies for cancer and other serious diseases, including mRNA-based vaccines.
Novavax
NVAX
Mkt Cap1.69B
Novavax, Inc. competes with IMV in the development of vaccines for infectious diseases, using its nanoparticle vaccine technology.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is a broad-based competitor, involved in the development of vaccines and therapeutics, including its partnership with BioNTech on a COVID-19 vaccine, competing with IMV's infectious disease focus.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson is involved in the research and development of vaccines and therapeutics for infectious diseases, making it a competitor in the same market as IMV.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. competes with IMV in the development of therapeutics for infectious diseases and cancer, with a focus on antiviral drugs.
AMGEN
AMGN
Mkt Cap236.38B
Amgen Inc. competes in the biotechnology space, focusing on innovative therapeutics, including immunotherapies, which puts it in competition with IMV.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals, Inc. is known for its development of monoclonal antibodies for the treatment of cancer and infectious diseases, competing with IMV's focus areas.
Novartis
NVS
Mkt Cap304.1B
Novartis AG competes with IMV in the development of novel healthcare solutions, including vaccines and cancer therapies, through its extensive research and development efforts.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC competes in the development of vaccines and therapeutics for infectious diseases and cancer, overlapping with IMV's research and development focus.

About

IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DPX platform, specifically engineered to attack cells expressing survivin. This compound is currently advancing through Phase II clinical studies for diffuse large B-cell lymphoma, ovarian cancer, and a variety of solid tumors including those affecting the bladder, liver, and MSI-H positive types. It is also in Phase I investigation for breast cancer. Additionally, the company's pipeline includes DPX-SurMAGE, undergoing Phase I clinical evaluation for bladder cancer, alongside the development of DPX-COVID-19 and DPX-RSV for addressing infectious diseases. The entity, previously known as Immunovaccine Inc., formally adopted the name IMV Inc. in May 2018. Established in 2000, IMV Inc. maintains its corporate headquarters in Dartmouth, Canada.
Show more...
CEO
Andrew Hall
Employees
63
Country
Canada
ISIN
JP3100760002

Listings

OTC Link
US
IMVIF
TSE
JP
7760.TSE

0 Comments

Share your thoughts

FAQ

What is IMV stock price today?▼
The current price of 7760.TSE is ¥2,070 JPY — it has decreased by -0.62% in the past 24 hours. Watch IMV stock price performance more closely on the chart.
What is IMV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Tokyo Stock Exchange exchange IMV stocks are traded under the ticker 7760.TSE.
Is IMV stock price growing?▼
7760.TSE stock has risen by +4.49% compared to the previous week, the month change is a +6.43% rise, over the last year IMV has showed a +13.99% increase.
What is IMV market cap?▼
Today IMV has the market capitalization of 17.27B
When is the next IMV earnings date?▼
IMV is going to release the next earnings report on November 06, 2026.
What were IMV earnings last quarter?▼
7760.TSE earnings for the last quarter are 5.01 JPY per share, whereas the estimation was N/A JPY resulting in a N/A surprise. The estimated earnings for the next quarter are N/A JPY per share.
What is IMV revenue for the last year?▼
IMV revenue for the last year amounts to 0 JPY.
What is IMV net income for the last year?▼
7760.TSE net income for the last year is -5.05B JPY.
Does IMV pay dividends?▼
Yes, 7760.TSE dividends are paid annual. The last dividend per share was 30 JPY. As of today, Dividend Yield (FWD)% is 1.45%.
How many employees does IMV have?▼
As of September 09, 2026, the company has 63 employees.
In which sector is IMV located?▼
IMV operates in the Health & Wellness sector.
When did IMV complete a stock split?▼
IMV has not had any recent stock splits.
Where is IMV headquartered?▼
IMV is headquartered in Dartmouth, Canada.